Yukimune Kanehira is an expert in Pharmacy at Yamagata University Hospital (Japan). Yukimune Kanehira has authored 7 publications, the most recent in 2025. SLR score: 16 (community average: 125). How the SLR is computed.

LeadR Profile

Profile validated by the expert
Yukimune Kanehira Yamagata University Hospital Japan
16 ScienceLeadR Reputation 16
Network Map

Pharmacy

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2019 - 2026
Source: PubMed

Yamagata University Hospital - Assistant professor

2025 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 7

Citations

Citations: 75 1st author: 2 Last author: 0 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis.
PMID 40345528 — fibrosis, pharmaceutical preparations, liposomes, collagen, pharmacy, enzymes, gelatin, matrix metalloproteinases, fibroblasts, therapeutics, retention, psychology, extracellular matrix, lip
J Pharm Sci20250
Heterogenous Intrapulmonary Distribution of Aerosolized Model Compounds in Mice with Bleomycin-Induced Pulmonary Fibrosis.
PMID 37843890 — idiopathic pulmonary fibrosis, bleomycin, administration, oral, lung, fibrosis, pharmaceutical preparations, imaging, three-dimensional, microscopy, pulmonary fibrosis, therapeutics, tissues, extracellular matrix
J Aerosol Med Pulm Drug Deliv20230
Aerosolized Liposomal Formulation Prevents Enhanced Drug Transfer from Fibrotic Lungs to the Systemic Circulation.
PMID 33372874 — solutions, plasma, epithelium, drug delivery systems, pharmaceutical preparations, cells, lung, idiopathic pulmonary fibrosis, tissues, indocyanine green, bleomycin
Curr Drug Deliv20200
Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer.
PMID 31204552 — technology, pharmaceutical, drug delivery systems, pharmaceutical preparations, cells, therapeutics, lung neoplasms, nanoparticles, vascular endothelial growth factor a, rna, small interfering, interleukin-6, administration, intravenous
Pharm Dev Technol20199
Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis.
PMID 25747986 — cells, idiopathic pulmonary fibrosis, lung, growth, fibrosis, pharmaceutical preparations, liposomes, collagen, fibroblast growth factor 2, pulmonary fibrosis, pharmacology, hydroxyproline, toxicology, fibroblasts, fibroblast growth factors
Biol Pharm Bull201521

LeadR Networks

Main global connection map